BRAF — A new player in hematological neoplasms

BRAF oncogenic kinase has become a target for specific therapy in oncology. Genetic characterization of a predominant V600E mutation in melanoma, thyroid cancer, and other tumors became a focus for developing specific inhibitors, such as vemurafenib or dabrafenib. Our knowledge regarding the role of...

Full description

Saved in:
Bibliographic Details
Published in:Blood cells, molecules, & diseases molecules, & diseases, 2014-06, Vol.53 (1-2), p.77-83
Main Authors: Machnicki, Marcin M., Stoklosa, Tomasz
Format: Article
Language:English
Subjects:
Animals
BRAF kinase
Hematologic Neoplasms - drug therapy
Hematologic Neoplasms - genetics
Hematologic Neoplasms - metabolism
Histiocytosis
Humans
Leukemia
Molecular Targeted Therapy
Mutation
Proto-Oncogene Proteins B-raf - antagonists & inhibitors
Proto-Oncogene Proteins B-raf - genetics
Proto-Oncogene Proteins B-raf - metabolism
V600E mutation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BRAF oncogenic kinase has become a target for specific therapy in oncology. Genetic characterization of a predominant V600E mutation in melanoma, thyroid cancer, and other tumors became a focus for developing specific inhibitors, such as vemurafenib or dabrafenib. Our knowledge regarding the role of mutated BRAF in hematological malignancies has grown quickly as a result of new genetic techniques such as next-generation sequencing. This review summarizes current knowledge regarding the role of BRAF in lymphoid and myeloid neoplasms, with a focus on hairy-cell leukemia, Langerhans cell histiocytosis, and Erdheim–Chester disease.
ISSN:1079-9796
1096-0961
DOI:10.1016/j.bcmd.2014.01.001